CTNNB1 and hepatocellular carcinoma: Thus, following this dose titration study in the β-N model, we determined that the 1mg/kg LNP-CTNNB1 dosage had profound in vivo efficacy for treatment of β-catenin-mutated HCC preclinical models without observable adverse effects.